MED Platform I, a mid-market buy-and-build fund, has attracted major commitments from a broad range of institutional investors and family offices across Europe (70%) and North America (30%). The over-subscribed fund held a final closing on July 31st, 2020 at a hard cap of € 1 billion. It targets growth companies in the European and North American mid-cap healthcare industries and provides the strategic, tactical and financial resources required to extend product lines and expand into new regions.

Denis Ribon, Founding Partner  of ArchiMed stated: “Since winning the mandate for our second small-cap fund mandate in 2017, CACEIS’ Private Equity team has proven to be a reliable servicing partner, demonstrating its ability to deliver the comprehensive set of services we need. With its fully-integrated front-to-back servicing and financing approach, CACEIS has set the benchmark on the European market against which other providers are measured.  By supporting our first two small cap funds, and our progression to the mid cap space, CACEIS has become a key partner in administering the €1.7bn under our management.”

Arnaud Garel-Galais, Group Head of PERES* Coverage and Business Development at CACEIS, added: “We are delighted that a leading Private Equity Healthcare specialist with a global reach like ArchiMed has reconfirmed its trust in our services and our staff by awarding us the mandate for their new MED Platform I fund. We have a detailed understanding of ArchiMed’s needs and have adapted and developed our services to meet their ongoing requirements. Furthermore, we are proud to service a fund with several portfolio companies that are playing a major role in tackling the COVID-19 pandemic.”

*PERES: Private Equity, Real Estate & Securitisation